Seattle, United States
AVM Biotechnology, a Seattle-based clinical-stage biotech company founded in 2008, is on a mission to Unleash the Potential of the Human Immune System. Led by the experienced Dr. Theresa Deisher, boasting an impressive track record with 47 patents and 4 discoveries in clinical trials, the company has been making waves with its lead drug, AVM0703. This innovative formulation of dexamethasone, administered at suprapharmacologic doses, works through a novel mechanism of action, mobilizing the body's own natural supercharged immune cells. AVM0703 shows promise in triggering the production and release of endogenous gamma delta+ Natural Killer T cells, positioning itself as an attractive candidate for addressing cancer, autoimmunity, and infectious diseases where limited treatment options exist.
Notably, AVM Biotechnology has garnered a $2.00M grant investment from the National Institutes of Health, underscoring its credibility and potential. Further enhancing its expertise, the company has assembled a Scientific Advisory Board comprising esteemed leaders in cancer and immunology, signaling a commitment to robust scientific guidance and growth.
The company's focus on developing products that improve outcomes without exacerbating patient suffering aligns with a core belief that side effects from treatments should never be worse than the diseases themselves. With its strong leadership, innovative approach, and promising developments, AVM Biotechnology stands as a compelling player in the biotechnology and pharmaceutical industries, poised to make significant contributions to the advancement of medical science.
